Vaxart Inc.
Edit

Vaxart Inc.

https://vaxart.com/
Last activity: 07.03.2024
Categories: CauseDeliveryHumanInvestmentPlatformPublic
Vaxart is a clinical-stage public company trading on NASDAQ under the symbol VXRT aimed at developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies have been completed; seasonal influenza, for which a Phase 2 challenge study was recently completed; and respiratory syncytial virus, or RSV, a common cause of respiratory tract infections. In addition, Vaxart has two programs targeting human papillomavirus, or HPV. The Company is developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18, and is also in Phase 2 with BTA074, an antiviral treatment for condyloma caused by HPV types 6 and 11. The company was founded in 2004 and has offices and laboratories in South San Francisco, CA.
Mentions
44
Location: United States, California, South San Francisco
Total raised: $9.27M
Email

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
19.01.2024-$9.27M-

Mentions in press and media 44

DateTitleDescriptionSource
07.03.2024Vaxart to Host Full Year 2023 Business Update and Financial ...-globenewsw...
19.01.2024Vaxart Receives $9.27 Million BARDA Project NextGen Award to...- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vacci...einpresswi...
19.01.2024Vaxart Receives $9.27 Million BARDA Project NextGen Award to...-globenewsw...
21.06.2023Vaxart Encourages All Stockholders of Record as of April 28,.../EIN News/ -- SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: V...einpresswi...
07.06.2023Vaxart, Inc. Announces Pricing of $15,000,000 Public Offerin...-globenewsw...
06.06.2023Vaxart, Inc. Announces Proposed Public Offering of Common St.../EIN News/ -- SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: V...einpresswi...
04.05.2023Vaxart Provides Business Update and Reports First Quarter 20.../EIN News/ -- On track to report key top line data from two Phase 2 norovirus vaccine studies mid-ye...einpresswi...
22.11.2022Vaxart to Present at World Vaccine & Immunotherapy Congr.../EIN News/ -- SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: V...einpresswi...
20.10.2022Vaxart to Host Third Quarter 2022 Business Update and Financ...Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE)...globenewsw...
10.10.2022Vaxart to Present at World Vaccine Congress Europe 2022 on O...SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today ann...globenewsw...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In